Safety and efficacy of SGLT2i administration in dilated cardiomyopathy: protocol for a systematic review and meta-analysis.

ABSTRACT:

Background

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a promising treatment for heart failure and cardiomyopathy. Furthermore, recent research has explored the use of SGLT2i in patients with dilated cardiomyopathy (DCM). However, the evidence that SGLT2i can improve left ventricular function and reduce symptoms of heart failure in DCM patients is limited.

Objective

The objective of our study was to assess the efficacy and safety of SGLT2i in managing DCM patients with heart failure and to predict its effectiveness in DCM patients without heart failure. The benefits of SGLT2i alone or in combination will also be determined.

Methods

A structured search of bibliographic databases (PubMed, Embase, and the Cochrane Central Register of Controlled Tr

SUBMITTER: Hu R 

PROVIDER: S-EPMC12463906 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature